Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Giant Cell Arteritis: early-phase trial registry

5 of 8 indexed Giant Cell Arteritis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 5 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Giant Cell Arteritis: 8 US clinical trials tracked, 5 recruiting.

Giant Cell Arteritis is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 4 of these trials.

Enrollment posture brief

Registry condition giant-cell-arteritis

OPEN 5 | RECR 63% | LATE 1 | EARLY 2 | RANK #2176 | SPON 4

Nearest open-share peer: Adolescent (63% recruiting · 16 trials)

Activity, Motor75%Giant Cell Arteritis (this)63%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Giant Cell Arteritis

Giant Cell Arteritis lists 5 open slots (63% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Giant Cell Arteritis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Giant Cell Arteritis is recruiting above its size-band peers.

    5 of 8 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Giant Cell Arteritis research.

    University of Pennsylvania accounts for 4 of 8 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Giant Cell Arteritis enrolment sits around 707 participants.

    Median target enrolment is 707 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.

  4. Giant Cell Arteritis research leans observational.

    3 interventional and 5 observational studies make up this index (37.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Giant Cell Arteritis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Abatacept Drug
2 trials
Placebo Drug
2 trials
placebo Combination
1 trials
mavrilimumab Combination
1 trials
prednisone Drug
1 trials
Magnetic Resonance Imaging (MRI) Diagnostic test
1 trials

US sites by state

Facility locations filed on Giant Cell Arteritis trials. A trial with sites in several states counts in each.

Pennsylvania 5 trials
Minnesota 5 trials
Ohio 4 trials
New York 4 trials
Utah 3 trials
Massachusetts 3 trials
Michigan 2 trials
Maryland 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Giant Cell Arteritis page

8 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Giant Cell Arteritis condition card totals 8 registered trials; most-linked intervention Abatacept; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.